Akèy › Limfòm folikilè
Etid klinik pou Limfòm folikilè ap rekrite nan Etazini
107 etid pou Limfòm folikilè ap rekrite patisipan nan sit atravè Etazini.
Vil ki gen plis etid
- New York City, NY24 etid
- Milwaukee, WI19 etid
- Nashville, TN18 etid
- Houston, TX18 etid
- Boston, MA17 etid
- Seattle, WA16 etid
- Baldwin Park, CA16 etid
- Durham, NC15 etid
- Columbus, OH13 etid
- Salt Lake City, UT12 etid
- Chicago, IL12 etid
- San Antonio, TX12 etid
- Philadelphia, PA12 etid
- Edison, NJ11 etid
- Los Angeles, CA11 etid
- Washington, DC11 etid
- Denver, CO11 etid
- Atlanta, GA11 etid
- Dallas, TX11 etid
- Jacksonville, FL10 etid
- Rochester, MN10 etid
- Cincinnati, OH9 etid
- New Haven, CT9 etid
- Cleveland, OH9 etid
- Portland, OR9 etid
- Miami, FL8 etid
- Pittsburgh, PA8 etid
- San Diego, CA8 etid
- Tampa, FL7 etid
- Charlotte, NC7 etid
- San Francisco, CA7 etid
- Cedar Rapids, IA7 etid
- Clifton, NJ7 etid
- Mountain View, CA7 etid
- Queens, NY7 etid
- Austin, TX6 etid
- Greenburgh, NY6 etid
- Winston-Salem, NC6 etid
- St. Louis, MO6 etid
- Ann Arbor, MI5 etid
Pa eta
- Alabama5 etid
- Arizona11 etid
- Arkansas3 etid
- Colorado14 etid
- Connecticut10 etid
- Delaware4 etid
- Distrik Columbia4 etid
- Florid25 etid
- Georgia14 etid
- Illinois14 etid
- Indiana7 etid
- Iowa9 etid
- Kalifòni36 etid
- Kansas7 etid
- Kentucky10 etid
- Lwizyàn8 etid
- Maryland9 etid
- Massachusetts20 etid
- Michigan12 etid
- Minnesota18 etid
- Mississippi3 etid
- Missouri9 etid
- Nebraska4 etid
- New Jersey15 etid
- New Mexico3 etid
- New York30 etid
- North Carolina23 etid
- Ohio23 etid
- Oklahoma4 etid
- Oregon11 etid
- Pennsylvania17 etid
- Rhode Island4 etid
- South Carolina6 etid
- Tennessee19 etid
- Texas35 etid
- Utah12 etid
- Virginia9 etid
- Washington20 etid
- Wisconsin21 etid
Etid ki fèk mete ajou
Tèks ofisyèl etid la (Anglè)
5HTP Regulation Of Asthma In Children
Ap rekriteFaz 2
Laj 8 a 18 · Tout sèks · Mizajou Oct 1, 2026 · NCT04160910Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Ap rekriteEtid obsèvasyon
Laj 0 a 38 · Tout sèks · Mizajou Oct 1, 2026 · NCT06131801Buprenorphine Implementation at Syringe Service Programs to Reduce Overdoses
Ap rekriteVolontè an sante akeyi
Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT07631598A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT06542250Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT06350318A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT05006716A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT03460977A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT07519772Epco, Zanu, Ritux for R/R FL or MZL
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06563596A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)
Ap rekriteFaz 2/3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT07634471Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Sep 23, 2026 · NCT06784167A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07226843A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT05765812Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients With Relapsed or Refractory Grade 1-3a Follicular Lymphoma
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT06453044A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07101328A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
Ap rekriteFaz 3
Laj 18 a 130 · Tout sèks · Mizajou Sep 21, 2026 · NCT06549595huCART19-IL18-eDHFR Cells in Relapsed/Refractory Follicular Lymphoma
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 16, 2026 · NCT07343934NEO100 and High-Grade Meningioma
Ap rekriteFaz 2
Laj 12 ak plis · Tout sèks · Mizajou Sep 15, 2026 · NCT05023018Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 11, 2026 · NCT06526793Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
Ap rekriteFaz 3
Laj 12 a 100 · Tout sèks · Mizajou Sep 11, 2026 · NCT06784752A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 11, 2026 · NCT06091254Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 9, 2026 · NCT07225439A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 4, 2026 · NCT06043323A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies
Ap rekriteEtid obsèvasyon
Laj 0 ak plis · Tout sèks · Mizajou Sep 2, 2026 · NCT07154823Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer
Ap rekriteFaz 3
Laj 12 ak plis · Tout sèks · Mizajou Sep 2, 2026 · NCT07215910Sous ClinicalTrials.gov, done yo ranmase Oct 2, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.